Steve Giordano
@Casdin Capital, Llc
Latest period2024 - Q3ReportedManaged Assets$1.5BTotal holdings35
Assets growth rate14.98%Assets growth rate (2-Q avg)5.98%Continuous growth in asset value1 quarters
Portfolio positions
This chart displays the top 10 holdings in Casdin Capital, Llc's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 35 positions.
Assets under management
The assets under management (AUM) of Casdin Capital, Llc over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 1.5B in assets, with a quarterly growth rate of 14.98% and a 2-quarter average growth rate of 5.98%. The portfolio is managed by Steve Giordano, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
LABStandard Biotools Inc
| 9.17% | $137.522M 71.255M shares@ $1.94 avg price | Increased 11.41% |
ILMNIllumina Inc
| 6.53% | $97.808M 750,000 shares@ $130.41 avg price | Increased 56.25% |
RLAYRelay Therapeutics Inc
| 4.37% | $65.498M 9.251M shares@ $7.09 avg price | Increased 9.5% |
CDXSCodexis Inc
| 1.67% | $24.948M 8.1M shares@ $3.08 avg price | Increased 305% |
VERVVerve Therapeutics Inc
| 1.29% | $19.339M 3.996M shares@ $4.85 avg price | Increased 30.62% |
BEAMBeam Therapeutics Inc
| 1.27% | $18.988M 775,000 shares@ $24.5 avg price | Increased 14.82% |
FDMT4d Molecular Therapeutics In
| 0.83% | $12.432M 1.15M shares@ $10.81 avg price | Increased 43.75% |
SNDXSyndax Pharmaceuticals Inc
| 0.61% | $9.144M 475,000 shares@ $19.25 avg price | Increased 216.67% |
GHGuardant Health Inc
| 0.54% | $8.029M 350,000 shares@ $22.94 avg price | Increased 250% |
IPSCCentury Therapeutics Inc
| 0.37% | $5.493M 3.212M shares@ $1.71 avg price | Increased 0.19% |